如今，在一项新的研究中，来自肯塔基大学马基癌症中心的研究人员发现了一种蛋白，它可能是开发三阴性乳腺癌新疗法的关键。相关研究结果近期发表在 Molecular Cancer 期刊上，论文标题为 “NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer”。

Gastrointestinal (GI) cancers are among the most common cancer types affecting millions worldwide with a poor survival rate ...

A defining feature of many cancers is genomic instability, which refers to the increased likelihood of acquiring mutations during cell division. These alterations can serve as potential biomarkers for ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

In addition to studying the immune system, you will take pathology, microbiology and biochemistry units. In the second year, you will study the cellular and molecular basis of cancer and its therapy ...

AstraZeneca, in partnership with the Moi Teaching & Referral Hospital (MTRH), has launched an advanced molecular testing ...

In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A University of California, Riverside team of scientists has used a novel approach to ...

(NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer ... AACR Symposium on Molecular Targets and ...